IP Library Granted Patent US 9,499,556
Granted Patent B2
US 9,499,556 · App. 14/529,368 · Granted Nov 22, 2016

Convenient preparation of N-substituted morphinan-6-ols from morphinan-6-ones

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,556
App. No.
14/529,368
Granted
Nov 22, 2016
Kind
B2
Abstract

Described herein are methods of preparing 6-hydroxy N-alkyl morphinan-6-ols from morphinan-6-ones, as illustrated below: wherein the variables R 1 , R 2 , R 3 , R 10 , R 11 , R 14 , and are as defined herein and wherein the reactions occur in a one-pot procedure using a boron based reducing agent.

Claims (43)

1. A method for preparing a compound of formula (I)

the method comprising,

(a) contacting a compound of formula (II)

with a carbonyl compound having formula:

to form an intermediate compound; and

(b) contacting the intermediate compound with a boron based reducing agent at a temperature of 0° C. or greater to form the compound of formula (I);

wherein:

is a single or double bond;

R 1 is H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, OH, or —O-Pro;

R 2 is H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, OH, or —O-Pro;

R 3 is H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, OH, or —O-Pro, wherein

Pro, at each occurrence, is independently a hydroxyl protecting group;

R 10 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, —C 1 -C 6 alkyl-C 3 -C 8 cycloalkyl, -C 2 -C 6 alkenyl-C 3 -C 8 cycloalkyl, -C 2 -C 6 alkynyl-C 3 -C 8 cycloalkyl, or C 1 -C 6 alkoxy-C 1 -C 6 alkyl;

R 11 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, —C 1 -C 6 alkyl-C 3 -C 8 cycloalkyl, -C 2 -C 6 alkenyl-C 3 -C 8 cycloalkyl, -C 2 -C 6 alkynyl-C 3 -C 8 cycloalkyl, or C 1 -C 6 alkoxy-C 1 -C 6 alkyl; and

R 14 is H or OH.

2. The method of claim 1 , wherein R 1 is H; R 2 is H; and R 3 is OH, methoxy or OPro.

3. The method of claim 1 , wherein the compound of formula (I) comprises a mixture of 6-α-hydroxy and 6-β-hydroxy epimers, the mixture of epimers having an epimeric ratio of 6-α-hydroxy to 6-α-hydroxy epimers of greater than or equal to 9:1.

4. The method of claim 1 , wherein the boron reducing agent comprises MBH n R 4-n , wherein M is Li, Na, or K; n is 1 or 2; and each R is independently —O 2 C—(C 1 -C 5 alkyl).

5. The method of claim 1 , wherein

R 10 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —C 1 -C 6 alkyl-C 3 -C 6 cycloalkyl, or allyl; and

R 11 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —C 1 -C 6 alkyl-C 3 -C 6 cycloalkyl, or allyl.

6. The method of claim 5 , wherein the boron reducing agent comprises MBH n R 4-n , wherein M is Li, Na, or K; n is 1 or 2; and each R is independently —O 2 C—(C 1 -C 5 alkyl).

7. The method of claim 6 , the contacting is conducted in a solvent chosen from DMF, DMA, NMP, or combinations thereof.

8. The method of claim 7 , wherein the solvent further comprises an acid.

9. The method of claim 1 , wherein the compound of formula (II) is noroxymorphone and the compound of formula (I) is nalbuphine or 6-α-naltrexol.

10. A method for preparing a compound of Formula (Ia) from a compound of formula (IIa), the method comprising:

(a) contacting the compound of formula (IIa) with a carbonyl compound having formula

to form an intermediate compound; and

(b) contacting the intermediate compound with a boron based reducing agent at a temperature of 0° C. or greater to form the compound of formula (Ia), according to the following reaction scheme:

wherein:

is a single or double bond;

R 3 is C 1 -C 6 alkoxy, OH, or O-Pro; wherein Pro is a hydroxyl protecting group;

R 10 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, or C- 1 -C 6 alkyl-C 3 -C 8 cycloalkyl;

R 11 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl-C 3 -C 8 cycloalkyl; and

R 14 is H or OH.

11. The method of claim 10 , wherein the boron reducing agent comprises MBH n R 4−n , wherein M is Li, Na, or K; n is 1 or 2; and each R is independently —O 2 C—(C 1 -C 5 alkyl).

12. The method of claim 10 , wherein R 3 is OH or methoxy.

13. The method of claim 12 , wherein R 10 is C 3 -C 6 cycloalkyl and R 11 is H.

14. The method of claim 13 , wherein the boron based reducing agent is a triacetoxyborohydride.

15. The method of claim 14 , wherein the contacting is conducted in a solvent chosen from DMF, DMA, NMP, or combinations thereof.

16. The method of claim 15 , wherein the solvent further comprises an acid.

17. The method of claim 10 , wherein the compound of formula (Ia) comprises a mixture of 6-α-hydroxy and 6-β-hydroxy epimers, the mixture of epimers having an epimeric ratio of 6-α-hydroxy to 6-βhydroxy epimers of greater than or equal to 9:1.

18. The method of claim 10 , wherein the compound of formula (IIa) and the compound of formula (Ia) independently have an optical activity of (−) or (+), and carbons C-5, C-13, C-14, and C-9, respectively, have a configuration of RRRR, RRSR, RRRS, RRSS, RSRR, RSSR, RSRS, RSSS, SRRR, SRSR, SRRS, SRSS, SSRR, SSSR, SSRS, or SSSS, provided that carbons C-15 and C-16 are both either on the alpha face of the molecule or the beta face of the molecule.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 039237, FRAME 0147 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0902 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jul 1, 2016
From: MALLINCKRODT LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 039237/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2015
From: WANG, PETER X.; JIANG, TAO
To: MALLINCKRODT LLC
Reel/Frame 035640/0332 →